No-one is safe until everyone is safe – patent waiver, compulsory licensing and COVID-19
Recentmonths have seen intensified global calls for an intellectual propertywaiver of COVID-19 related vaccines, treatments and related products.Where one side of the debate elevates Intellectual Property Rights as on obstacle to affordable and expeditious global access to vaccines and treatments, the other side of the debate points to the existing TRIPS flexibilities such as compulsory licensing,